Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study

BACKGROUND: Owing to the emergence of drugs targeting human epidermal growth factor receptor 2 (HER2), remarkable prognostic enhancement has been seen for patients with HER2-positive breast carcinoma. However, anti-HER2 medicines are applicable merely to individuals with HER2-positive tumors, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang-Gen, Li, Yi-Fan, Ma, Tian-Yi, Lv, Meng, Lv, Zhi-Dong, Wang, Yuan-Yuan, Liu, Xiang-Ping, Mao, Yan, Wang, Hai-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090461/
https://www.ncbi.nlm.nih.gov/pubmed/37064133
http://dx.doi.org/10.3389/fonc.2023.1130734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090461/
https://www.ncbi.nlm.nih.gov/pubmed/37064133
http://dx.doi.org/10.3389/fonc.2023.1130734

Ejemplares similares